Treponema Pallidum Haemagglutination Assay (TPHA)

Alternative names
Treponema Pallidum Haemagglutination Assay (TPHA), syphilis, kit
Primary use
Diagnosis / Measurement / Monitoring
Type of medical device or related product
In vitro diagnostic tests
General vs. specific use (health condition)
Specific
Intended population age
Later adults (over 64 years)
Adults (20 to 64 years)
Adolescent (10 to 19 years)
Childhood (28 days to 9 years)
Intended population sex
All
Level of technical knowledge
Specialized clinical
Capital
No
Reusable
No
Requirements
None
WHO list of priority medical devices
Reproductive, maternal, newborn and child health (2015)
Service delivery platforms / Healthcare levels
Second-level and third-level hospital services and specialized outpatient services
Healthcare unit
Laboratory
EMDN related code(s)
W0105010302
SYPHILIS ANTIBODY ASSAYS TOTAL
The code(s) and term(s) in this section were observed and retrieved from public databases and have not been validated by health regulatory authorities. Please consult your regulatory agency and EMDN site: https://webgate.ec.europa.eu/dyna2/emdn
GMDN related code(s)
51798
Treponema pallidum total antibody IVD, kit, enzyme immunoassay (EIA) (A collection of reagents and other associated materials intended to be used for the qualitative and/or quantitative detection of total antibodies to Treponema pallidum in a clinical specimen using an enzyme immunoassay (EIA) method. The assay is designed to detect infection with Treponema pallidum, the bacteria associated with syphilis.)
The medical device term(s), code(s) and definition(s) in this section were retrieved from databases external to WHO. As there might be more than one name, definition and “Nomenclature Code” related to the specific medical device, please consult https://gmdnagency.org GMDN ®. © GMDN Agency 2005-2024 
Decommissioning
WHO resources on medical devices